{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-004975","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.287448+00:00","generated_at":"2026-06-12T09:06:22.330131+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aligos reports Q2 net loss $18.8M; cash $90.8M; NASH program on track for Q4 Phase 2a filing","bullets":["Net loss $18.8M ($0.43/shr) vs $19.9M ($0.47) in Q2 2022.","Cash $90.8M at June 30, 2023, down from $125.8M; sufficient through end 2024.","NASH candidate ALG-055009 Phase 1 complete; Phase 2a protocol filing expected Q4 2023; topline data Q4 2024.","COVID-19 protease inhibitor ALG-097558: first-in-human dosing ongoing; topline data H1 2024.","Agreement in principle with Janssen to resolve litigation; case stayed July 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-004975","json":"https://secwatch.observer/filing/0001171843-23-004975.json","markdown":"https://secwatch.observer/filing/0001171843-23-004975.md","text":"https://secwatch.observer/filing/0001171843-23-004975.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184323004975/0001171843-23-004975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184323004975/f8k_080323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T09:06:22.330131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b193574da12920a91400a3a2c4ed2fefdbad1cb","claim":"Aligos Therapeutics, Inc. reported three months ended June 30, 2023 results: net income $18.8 million, EPS $(0.43).","evidence_excerpt":"Net losses for the three months ended June 30, 2023, were $18.8 million or basic and diluted net loss per common share of $(0.43), compared to net losses of $19.9 million or basic and diluted net loss per common share of $(0.47) for the three months ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000117184323004975/0001171843-23-004975-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended June 30, 2023"},{"label":"Net income","value":"$18.8 million"},{"label":"EPS","value":"$(0.43)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}